

„Drug Repurposing“ – die aktuell schärfste Waffe gegen COVID-19

MARKUS DEPFENHART¹, DANIELLE DE VILLIERS², MARINA RAUTENBACH³,
GOTTFRIED LEMPERLE⁴, MARKUS MEYER⁵, SALVATORE DI SOMMA^{6,7}
HAMBURG, PRETORIA, SAN DIEGO, JAKARTA, ROM

1. World Health Organization (2020) Coronavirus disease (COVID-2019) situation reports 1–124. <https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports>
2. Virological.org (2020) Novel 2019 coronavirus genome. <http://virological.org/t/novel-2019-coronavirus-genome/319>
3. GSAID Database (2020) Coronavirus. <https://www.gisaid.org/CoV2020/>
4. GenBank. (2020) SARS-CoV-2 (Severe acute respiratory syndrome coronavirus 2) sequences. <https://www.ncbi.nlm.nih.gov/genbank/sars-cov-2-seqs/>
5. Regulatory Affairs Professionals Society (2020) Covid-19 vaccine tracker. <https://www.raps.org/news-and-articles/news-articles/2020/3/covid-19-vaccine-tracker>
6. Li G, De Clercq E (2020) Therapeutic options for the 2019 novel coronavirus (2019-nCoV). *Nat Rev Drug Discov* 19: 149–150
7. Wang M, Cao R, Zhang L, et al (2020) Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. *Cell Res* 30: 269–271
8. Simmons G, Zmora P, Gierer S, et al (2013) Proteolytic activation of the SARS-coronavirus spike protein: cutting enzymes at the cutting edge of antiviral research. *Antiviral Res* 100: 605–614
9. Belouzard S, Millet JK, Licitra BN, Whittaker GR (2012) Mechanisms of coronavirus cell entry mediated by the viral spike protein. *Viruses* 4: 1011–1033
10. Simmons G, Gosalia DN, Rennekamp AJ, et al (2005) Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry. *Proc Natl Acad Sci USA* 102: 11876–11881
11. Rubio Aliaga I, Frey I, Boll M, et al (2003) Targeted disruption of the peptide transporter *Pept2* gene in mice defines its physiological role in the kidney. *Mol Cell Biol* 23: 3247–3252
12. Ding N, Zhao K, Lan Y, et al (2017) Induction of atypical autophagy by porcine hemagglutinating encephalomyelitis virus contributes to viral replication. *Front Cell Infect Microbiol* 7: 56–56
13. Frlan R, Gobec S (2006) Inhibitors of cathepsin B. *Curr Med Chem* 13: 2309–2327
14. Colson P, Rolain JM, Raoult D (2020) Chloroquine for the 2019 novel coronavirus SARS-CoV-2. *Int J Antimicrob Agents* 55: 105923
15. Gao J, Tian Z, Yang X (2020) Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. *Biosci Trends* 14: 72–73
16. Vincent MJ, Bergeron E, Benjannet S, et al (2005) Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. *Virology* 339: 723–734
17. Keyaerts E, Li S, Vijgen L, et al (2009) Antiviral activity of chloroquine against human coronavirus OC43 infection in newborn mice. *Antimicrob Agents Chemother* 53: 3416–3421
18. Tan YW, Yam WK, Sun J, Chu JH (2018) An evaluation of chloroquine as a broad-acting antiviral against hand, foot and mouth disease. *Antiviral Res* 149: 143–149
19. McChesney EW. (1983) Animal toxicity and pharmacokinetics of hydroxychloroquine sulfate. *The Am J Med* 75: 11–18
20. Hoffmann M, Kleine-Weber H, Schroeder S, et al (2020) SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. *Cell*. doi: 10.1016/j.cell.2020.02.052
21. Drugs (2020) Camostat. [Cited 2020 May 25]. Available from: <https://www.drugs.com/international/camostat.html>.
22. Ramsey ML, Nuttall J, Hart PA (2019) On behalf of the TIT. A phase 1/2 trial to evaluate the pharmacokinetics, safety, and efficacy of NI-03 in patients with chronic pancreatitis: study protocol for a randomized controlled trial on the assessment of camostat treatment in chronic pancreatitis (TACTIC). *Trials* 20: 501. doi: 10.1186/s13063-019-3606-y
23. Lucas JM, Heinlein C, Kim T, et al (2014) The androgen-regulated protease TMPRSS2 activates a proteolytic cascade involving components of the tumor microenvironment and promotes prostate cancer metastasis. *Cancer Discov* 4: 1310–1325
24. Depfenhart M, Lemperle G, Meyer M, et al (2020) A SARS-CoV-2 prophylactic and treatment; a counter argument against the sole use of chloroquine. *Am J Biomed Sci & Res* 8: 248–251 (<https://biomedgrid.com/pdf/AJBSR.MS.ID.001283.pdf>)
25. Depfenhart M, de Villiers D, Lemperle G, et al (2020) Potential new treatment strategies for COVID-19: is there a role for bromhexine as add-on therapy? *Intern Emerg Med* [ahead of print] doi: 10.1007/s11739-020-02383-3

26. Laporte M, Naesens L (2017) Airway proteases: an emerging drug target for influenza and other respiratory virus infections. *Curr Opin Virol* 24: 16–24
27. Han S, Mallampalli RK (2015) The role of surfactant in lung disease and host defense against pulmonary infections. *Ann Am Thorac Soc* 12: 765–774
28. Plomer M, de Zeeuw J (2017) Mehr als ein Expektorans: neue wissenschaftliche Daten zu Ambroxol im Kontext der Behandlung bronchopulmonaler Erkrankungen. *MMW Fortschritte der Medizin* 159: 22–33
29. Gao X, Huang Y, Han Y, et al (2011) The protective effects of ambroxol in pseudomonas aeruginosa-induced pneumonia in rats. *Arch Med Sci* 7: 405–413
30. Holshue ML, DeBolt C, Lindquist S, et al (2020) First case of 2019 novel coronavirus in the United States. *N Engl J Med* 382: 929–936
31. Ledford H. (2020) Hopes rise for coronavirus drug remdesivir [ahead of print]. *Nature*. doi:10.1038/d41586-020-01295-8